CelLBxHealth (CLBX) Aktienübersicht
ANGLE plc, ein Unternehmen für medizinische Diagnostik, entwickelt Produkte für die Krebsdiagnostik im Vereinigten Königreich, in Europa, Nordamerika und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
+ 2 mehr Risiken
CLBX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CelLBxHealth plc Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | UK£0.014 |
| 52-Wochen-Hoch | UK£0.08 |
| 52-Wochen-Tief | UK£0.0085 |
| Beta | 0.43 |
| 1 Monat Veränderung | -22.54% |
| 3 Monate Veränderung | 52.78% |
| 1 Jahr Veränderung | -76.09% |
| 3 Jahre Veränderung | -88.54% |
| 5 Jahre Veränderung | -98.76% |
| Veränderung seit IPO | -99.08% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jun 22
CLBX: Lung Cancer Study And Big Pharma Agreement Will Drive Future Upside
Analysts have kept their fair value estimate for CelLBxHealth steady at £0.04, with only marginal adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E feeding into the latest price target update. What's in the News CelLBxHealth PLC entered into a Master Services Agreement with AstraZeneca PLC, establishing CelLBxHealth as a qualified service provider to support drug discovery and development using CTC powered analytics of clinical trial samples with the Parsortix platform.Narrative-Update • Jun 05
CLBX: Lung Cancer Study Will Support Future Upside Narrative
Analysts have maintained their fair value estimate for CelLBxHealth at £0.04 per share. A slightly lower discount rate and marginal adjustments to assumptions for revenue growth, profit margin and future P/E have resulted in an unchanged price target.Narrative-Update • May 22
CLBX: Lung Cancer Study And New Sales Leadership Will Drive Upside
Analysts have slightly revised their price target for CelLBxHealth, keeping fair value at £0.04 while fine tuning assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News CelLBxHealth issued revenue guidance for fiscal 2026, indicating an expectation of at least £2.1 million, described as a 50% increase on fiscal 2025, alongside ongoing cost reduction efforts (Corporate Guidance).Recent updates
Narrative-Update • Jun 22
CLBX: Lung Cancer Study And Big Pharma Agreement Will Drive Future Upside
Analysts have kept their fair value estimate for CelLBxHealth steady at £0.04, with only marginal adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E feeding into the latest price target update. What's in the News CelLBxHealth PLC entered into a Master Services Agreement with AstraZeneca PLC, establishing CelLBxHealth as a qualified service provider to support drug discovery and development using CTC powered analytics of clinical trial samples with the Parsortix platform.Narrative-Update • Jun 05
CLBX: Lung Cancer Study Will Support Future Upside Narrative
Analysts have maintained their fair value estimate for CelLBxHealth at £0.04 per share. A slightly lower discount rate and marginal adjustments to assumptions for revenue growth, profit margin and future P/E have resulted in an unchanged price target.Narrative-Update • May 22
CLBX: Lung Cancer Study And New Sales Leadership Will Drive Upside
Analysts have slightly revised their price target for CelLBxHealth, keeping fair value at £0.04 while fine tuning assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News CelLBxHealth issued revenue guidance for fiscal 2026, indicating an expectation of at least £2.1 million, described as a 50% increase on fiscal 2025, alongside ongoing cost reduction efforts (Corporate Guidance).Narrative-Update • May 04
CLBX: Lung Cancer Collaboration And Cost Discipline Will Support Future Upside
Analysts have reduced their price target for CelLBxHealth from £0.07 to £0.04. This reflects updated assumptions around discount rates, profit margins, and a lower future P/E multiple.
Narrative-Update • Apr 19
CLBX: Regulatory Streamlining And Refocused Resources Will Support Future Upside Potential
Analysts have adjusted their price target on CelLBxHealth, highlighting higher assumed revenue growth, a wider profit margin and a lower future P/E multiple as key inputs to their revised fair value view. What's in the News CelLBxHealth decided to discontinue maintenance of its FDA establishment license and device listing for the Parsortix system, aligning its regulatory approach with current operational and commercial priorities (Key Developments).Narrative-Update • Apr 04
CLBX: Cost Discipline And Refocused Regulatory Approach Will Support Future Oncology Upside
Analysts have kept their fair value estimate for CelLBxHealth steady at £0.07 per share, with a slightly higher discount rate and a small adjustment to long term profit margin and future P/E assumptions guiding this latest price target update. What's in the News CelLBxHealth decided to discontinue maintenance of its FDA establishment license and device listing for the Parsortix system, aligning its regulatory approach with current operational and commercial priorities while focusing on cost discipline (Key Developments).Narrative-Update • Mar 20
CLBX: Cost Discipline And Regulatory Streamlining Will Support Future Oncology Upside
CellBxHealth’s analyst price target has been reset to £0.07. Analysts attribute this to consistent fair value assumptions, a slightly lower discount rate, a marginally higher profit margin outlook, and a modestly reduced future P/E multiple.Narrative-Update • Mar 06
CLBX: Cost Discipline And Refocused Resources Will Support Oncology Upside
Analysts have modestly raised their price target on CelLBxHealth, citing an unchanged intrinsic value estimate of about £0.07 per share, slightly higher assumed discount rates, a marginally higher future P/E expectation, and a small reduction in projected profit margins. What's in the News CelLBxHealth plc decided to discontinue maintenance of its FDA establishment license and device listing for the Parsortix system, aligning regulatory obligations with current operational and commercial priorities (Key Developments).Narrative-Update • Feb 19
CLBX: Equity Raises And Lower Risk Profile Will Support Oncology Upside
Analysts have raised their target price for CelLBxHealth to £0.07. The updated view reflects revised assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples.
Narrative-Update • Feb 05
CLBX: Future Repricing Will Rely On Equity Raises And Margin Expansion
Analysts have raised their price target for CelLBxHealth, citing slightly lower assumed discount rates, a modest uptick in projected revenue growth and profit margins, and a reduced future P/E of about 45x as the main factors behind the change. What's in the News CelLBxHealth completed a follow-on equity offering of £7.208915 million, issuing multiple blocks of ordinary shares at £0.01 per share.Narrative-Update • Jan 22
CLBX: Equity Raises And QIAGEN Alliance Will Support Future Upside Potential
Analysts have trimmed their fair value estimate for CelLBxHealth from US$0.17 to US$0.04. This reflects updated assumptions around revenue growth, profit margins, discount rate and future P/E expectations.Narrative-Update • Jan 08
CLBX: Future Profitability Assumptions Will Drive Bullish Repricing Potential
Analysts have reduced their price targets on CelLBxHealth, citing updates to fair value assumptions, a higher discount rate, more moderate revenue growth expectations, improved profit margin estimates toward 9.49%, and a revised future P/E of about 53.37x. What's in the News CelLBxHealth plc has filed follow on equity offerings totaling £8.67 million across multiple tranches of ordinary shares at £0.01, including securities with a subsequent direct listing feature.Narrative-Update • Dec 23
CLBX: Equity Raises Will Drive Future Oncology Partnerships And Upside Potential
Analysts have nudged their price target on CelLBxHealth slightly higher to reflect updated valuation models, with modest adjustments to the discount rate, long term profit margin expectations, and forward earnings multiples. These revisions now support an intrinsic value estimate of approximately $0.07 per share.Narrative-Update • Dec 09
CLBX: Equity Raises Will Fund Future Oncology Partnerships And Upside Potential
Analysts have lowered their price target on CelLBxHealth from approximately $0.11 to $0.07 per share, citing a higher required discount rate, more conservative long term revenue growth assumptions, and a higher future P/E multiple that together point to a more tempered outlook for upside. What's in the News CelLBxHealth completed a £7.21 million follow on equity offering, issuing over 720 million ordinary shares at £0.01 per share, alongside a subsequent direct listing (company filing).Narrative-Update • Nov 25
CLBX: New Partnerships And Equity Raise Will Drive 2025 Performance
Narrative Update on CelLBxHealth Analysts have maintained CelLBxHealth's target price at $0.11 per share, citing improved profit margin estimates and a slightly higher discount rate in their updated valuation model. What's in the News Entered a non-exclusive collaboration and co-marketing agreement with QIAGEN Manchester Ltd., allowing the Parsortix platform to be offered in pharmaceutical projects that combine CTC enrichment and molecular analysis tools (Key Developments) Completed a follow-on equity offering totaling £6.8 million through the issuance of common stock (Key Developments) Filed additional follow-on equity offerings amounting to £1 million and £8.67 million to raise further capital (Key Developments) Special/Extraordinary Shareholders Meeting scheduled for December 15, 2025, in London (Key Developments) Changed company name from ANGLE plc to CelLBxHealth plc effective October 29, 2025 (Key Developments) Valuation Changes Fair Value estimate remains stable at $0.105 per share, showing no change from previous assessments.Narrative-Update • Nov 10
CLBX: Revenue Shifts And Leadership Changes Will Shape 2025 Outlook
Analysts have revised their price target for CelLBxHealth, maintaining the fair value at $0.105. Adjustments in the discount rate reflect a reassessment of market conditions and risk profiles.Narrative-Update • Oct 27
Leadership Appointment And Diagnostic Partnerships Will Shape Future Market Expansion
Analysts have maintained ANGLE's fair value estimate at $0.11 per share. Their outlook remains steady after a review of updated company fundamentals and underlying discount rates.Narrative-Update • Oct 13
Pharma Partnerships And Liquid Biopsy Will Expand Future Markets
Analysts have lowered their price target for ANGLE from $0.17 to $0.105. They cite updated projections of higher revenue growth, but reduced profit margins and a higher discount rate are impacting the company's fair value assessment.Narrative-Update • Sep 11
Pharma Partnerships And Liquid Biopsy Will Expand Future Markets
Despite a substantial increase in consensus revenue growth forecasts, ANGLE’s future P/E multiple has halved, reflecting a notable de-rating and driving the fair value estimate down from £0.28 to £0.17. What's in the News ANGLE plc announced a collaboration with Myriad Genetics, utilising ANGLE's Parsortix system to process cancer patient blood samples for molecular analysis, comparing CTC-DNA with matched tissue samples via Myriad's assay; further details remain confidential.Neues Narrative • Jun 01
Pharma Partnerships And Liquid Biopsy Will Expand Future Markets
ANGLE's unique technologies and partnerships in precision oncology position it for strong, margin-expanding revenue growth as liquid biopsy adoption accelerates.Analyseartikel • May 30
Is ANGLE (LON:AGL) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analyseartikel • Jan 22
Here's Why We're Watching ANGLE's (LON:AGL) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Sep 27
Will ANGLE (LON:AGL) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analyseartikel • Mar 20
We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analyseartikel • Dec 02
Will ANGLE (LON:AGL) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analyseartikel • Aug 11
We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Feb 28
We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyseartikel • Jul 16
ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Aktionärsrenditen
| CLBX | GB Medical Equipment | GB Markt | |
|---|---|---|---|
| 7D | -14.1% | -0.7% | -1.4% |
| 1Y | -76.1% | -3.8% | 15.6% |
Rendite im Vergleich zur Industrie: CLBX unter dem Niveau der Branche UK Medical Equipment , die im vergangenen Jahr eine Rendite von -3.8% erzielte.
Rendite vs. Markt: CLBX hinter dem Markt UK zurück, der im vergangenen Jahr eine Rendite von 15.6 erzielte.
Preisvolatilität
| CLBX volatility | |
|---|---|
| CLBX Average Weekly Movement | 17.0% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.8% |
Stabiler Aktienkurs: Der Aktienkurs von CLBX war in den letzten 3 Monaten im Vergleich zum UK -Markt volatil.
Volatilität im Zeitverlauf: CLBXDie wöchentliche Volatilität (17%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der UK Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1994 | 119 | n/a | cellbxhealth.com |
ANGLE plc, ein Unternehmen für medizinische Diagnostik, entwickelt Produkte für die Krebsdiagnostik im Vereinigten Königreich, in Europa, Nordamerika und international. Das Unternehmen entwickelt Parsortix PC1-Systeme, ein medizinisches Gerät zur Erfassung und Gewinnung intakter zirkulierender Tumorzellen (CTCs) aus dem Blut von Patientinnen mit metastasierendem Brustkrebs für die anschließende benutzervalidierte Analyse. Das Unternehmen bietet auch das Portrait+ CTC-Färbekit an, ein gebrauchsfertiges Laborkit mit hoher analytischer Sensitivität und Spezifität für die Identifizierung, Charakterisierung und Auszählung von epithelialen und mesenchymalen Übergängen, sowie CellKeep Slide, eine Technologie zur Gewinnung von CTCs.
CelLBxHealth plc's Grundlagenzusammenfassung
| CLBX grundlegende Statistiken | |
|---|---|
| Marktanteil | UK£15.63m |
| Gewinn(TTM) | -UK£15.78m |
| Umsatz(TTM) | UK£2.62m |
6.0x
Kurs-Umsatz-Verhältnis-1.0x
Kurs-Gewinn-Verhältnis Ist CLBX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CLBX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | UK£2.62m |
| Kosten der Einnahmen | UK£1.80m |
| Bruttogewinn | UK£823.00k |
| Sonstige Ausgaben | UK£16.60m |
| Gewinn | -UK£15.78m |
Zuletzt gemeldete Gewinne
Jun 30, 2025
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.014 |
| Bruttomarge | 31.36% |
| Nettogewinnspanne | -601.37% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich CLBX auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/13 01:39 |
| Aktienkurs zum Tagesende | 2026/07/13 00:00 |
| Gewinne | 2025/06/30 |
| Jährliche Einnahmen | 2024/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
CelLBxHealth plc wird von 4 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Adam McCarter | Cavendish |
| Lucy Codrington | Edison Investment Research |
| Lucy Codrington | Jefferies LLC |